ReviewNature reviews. Drug discovery2016
Central nervous system myeloid cells as drug targets: current status and translational challenges.
Review in Nature reviews. Drug discovery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of convergent ion channel pathways in microglial phenotypes: a systematic review of the implications for neurological and psychiatric disorders.Translational psychiatry · 2018Pooled it
- FABP7 is increased in progressive multiple sclerosis and induces a pro-inflammatory phenotype in monocytes through a glycolytic switch.Nature communications · 2025Article
- Inhibition of tumour necrosis factor alpha by Etanercept attenuates Shiga toxin-induced brain pathology.Journal of neuroinflammation · 2025Article
- A Mouse Model of Sporadic Alzheimer's Disease with Elements of Major Depression.Molecular neurobiology · 2025Article
- Lipofuscin-like autofluorescence within microglia and its impact on studying microglial engulfment.Nature communications · 2023Article
- A comparative analysis of microglial inducible Cre lines.Cell reports · 2023Article
- A backpack-based myeloid cell therapy for multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Morphofunctional Features of Microglial Cells during the Administration of Orexin A.Bulletin of experimental biology and medicine · 2023Article
- A comparative analysis of microglial inducible Cre lines.bioRxiv : the preprint server for biology · 2023Article
- Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination.Molecular neurodegeneration · 2022Article
- Emerging Role of NLRP3 Inflammasome/Pyroptosis in Huntington's Disease.International journal of molecular sciences · 2022Review
- Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function.Acta neuropathologica · 2022Review
- Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.Drug design, development and therapy · 2022Review
- Xiaoyaosan Ameliorates Chronic Restraint Stress-Induced Depression-Like Phenotype by Suppressing A2AR Signaling in the Rat Striatum.Frontiers in pharmacology · 2022Article
- Role of TREM2 in Alzheimer's Disease: A Long Road Ahead.Molecular neurobiology · 2021Review
- Links between Immune Cells from the Periphery and the Brain in the Pathogenesis of Epilepsy: A Narrative Review.International journal of molecular sciences · 2021Review
- Article
- Immune Actions on the Peripheral Nervous System in Pain.International journal of molecular sciences · 2021Review
- Virus-infection in cochlear supporting cells induces audiosensory receptor hair cell death by TRAIL-induced necroptosis.PloS one · 2021Article
- Deciphering the heterogeneity of myeloid cells during neuroinflammation in the single-cell era.Brain pathology (Zurich, Switzerland) · 2020Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid cells of the central nervous system (CNS), which include parenchymal microglia, macrophages at CNS interfaces and monocytes recruited from the circulation during disease, are increasingly being recognized as targets for therapeutic intervention in neurological and psychiatric diseases. The origin of these cells in the immune system distinguishes them from ectodermal neurons and other glia and endows them with potential drug targets distinct from classical CNS target groups. However, despite the identification of several promising therapeutic approaches and molecular targets, no agents directly targeting these cells are currently available. Here, we assess strategies for targeting CNS myeloid cells and address key issues associated with their translation into the clinic.
Indexed as
Identifiers
26634996What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.